MD Becker Partners has authored or contributed to other articles, journal publications, and abstracts.
Note: access to full text versions may be available by clicking on the story dates below.
12/4/2010 – “Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies” in Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 1783
12/8/2008 – “Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy” in Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2987
7/1/2008 – “The use of chelated radionuclide (samarium-153-ethylene-diamine-tetra-methylene-phosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing” in Clin Cancer Res 2008 Jul 1;14(13):4241-9
9/12/2006 – “Development of optimal Lu-177 labeled monoclonal antibody (7E11) constructs (CYT-500) for radioimmunotherapy of hormone refractory prostate cancer” Abstract #B45 from the 2006 American Association for Cancer Research (AACR) annual meeting
